Table 2:

Druggable gene targets and FDA approved drugs that can be potentially repurposed for neglected otologic diseases

Regulons	Gene	Pharmacologic drug class	Stria vascularis cell types*	FDA-approved drugs
				Activator	Inhibitor	Unknown
Esrrb regulons	Pde4	Enzyme	IC, SR, BC		Chlorine theophyllinate Rofumilast Amlexano Flavoxate Bufylline
	Prkcd	Kinase	MC			Inge nol Meb utate
	Fgfr1	Kinase	MC, BC		Lenvatinib Ponatinib	Sora tenib
	Adora1	GPCR	MC	Adenosine	Theophylline Bufylline Caffeine
	Esrrb		MC			Estra diol
	P2ry2	GPCR	MC, BC	Diquofisol
	Kcnma1	Ion channel	MC	Chlorzoxazone
	Ano1	Ion channel	MC			Crof Elem er
	Hdac5	Enzyme	All SV cell types		Panobinostat Belinostat
	Ghr	Receptor	All SV cell types	Somatremm Somatotropin	Pegvisimont
	Igf1r	Kinase	All SV cell types	Mescasermin	Brigatinib	Certi nib
Bmyc regulons	Ca14	Enzyme	All SV cell types		Furosemide Zoledronic Acetazolamide Dichlorphenamide Ethoxzolamide
	Cdk4	Kinase	All SV cell types		Palbociclib Ribociclib
	Atp1a4	Transporter	BC, Fc		Deslanoside Digoxin Acetyldigoxin
	Abca1	Transporter	IC > MC		Probucol
	Grik5	Ion channel	All SV cell types		Topiramate
	Ano1	Ion channel	MC			Crof Elem er
	Ndufb2	Enzyme	All SV cell types		Metformin
	Tyr	Enzyme	IC		Mequinol Monobenzone Avobenzone
	Rarg	Receptor	All SV cell types	Acitretin
	Rara	Receptor	MC	Etretinate Acitretin Tazarotene Aliretinoin Adapalene
	Rarb	Receptor	IC > BC, SR	Tazarotene Aliretinoin		Ada pale ne

^*Stria vascularis (SV) cell types in which the genes are predominantly expressed. Marginal cell (MC), Intermediate cell (IC), Basal cell (BC), Spindle-root cells (SR), Fibrocyte (Fc)

Adapted from Korrapati et al,. 2019